0.01
-6.67%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Atomo Diagnostics
Its shares trade on ASX under the ticker AT1.AX. It has been listed since 16 April 2020. In the fiscal year to 30 June 2026, it reported revenue of A$5.3m and a net loss of A$3.5m. At that date it held total assets of A$10.8m and shareholders' equity of A$7.7m.
Atomo Diagnostics Ltd. engages in manufacturing, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. The firm supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The firm has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation and female health. Its products include Atomo HIV Self-Test, AtomoRapid HIV (1&2) and ATOMONOW Pregnancy Test. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. Its AtomoRapid HIV (1&2) integrates multiple test components into the device platform. AtomoRapid HIV (1&2) needs a small drop of blood to give results in 15 minutes.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 16 Apr 2020
- Website
- atomodiagnostics.com ↗
Leadership
Pay as last reported
- Mr. Patrick CookIndependent Chairman of the Board
- Mr. John KellyChief Executive Officer, Founder, Managing Director, DirectorA$533,091
- Mr. Chandra SukumarChief Operating OfficerA$72,644
- Mr. Mathew WatkinsCompany Secretary
- Mr. Anthony MayDirector
- Dr. Curt LaBelleNon-Executive DirectorA$50,000
- Ms. Deborah NeffNon-Executive Independent DirectorA$53,880
- Dr. Cheri WalkerNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Patented devices simplify testing procedures and enhance usability for rapid point-of-care and at-home testing.
- Commercialized products include Atomo HIV Self-Test, AtomoRapid HIV (1&2), and ATOMONOW Pregnancy Test.
- Supply agreements target infectious diseases including COVID-19, HIV, viral vs bacterial differentiation, and female health.
Weaknesses
- No specific weaknesses mentioned in the provided information.
- No details on financial performance or market share provided.
- No information on production capacity or scalability of manufacturing.
Opportunities
- Expansion into global diagnostic markets with integrated RDT devices.
- Growing demand for rapid diagnostic testing for infectious diseases.
- Potential for new supply agreements targeting additional health applications.
Threats
- Competition in the rapid diagnostic testing market for blood-based devices.
- Regulatory challenges in international markets for medical devices.
- Dependence on supply agreements for specific testing applications.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.